Stereotactic Hypofractionated Irradiation for Metastatic, Inoperable, and Recurrent Malignancies: A Modern Necessity, rather than a Luxury

Table 7

Trials using SABR for early stage lung cancers.

Trial	Remarks	Outcome
Lagerwaard et al. [70]	SABR (60 Gy in 3, 5, or 8 fractions depending on tumour size and location) in potentially operable patients.	LC at 1 and 3 years were 98% and 93%, respectively. Less than 3% risk of grade 3 toxicity. Median OS exceeded 5 years. 30-day postprocedure mortality was 0%.
Chan et al. [71]	16 stage-1 NSCLC medically inoperable with a median age of 82 years.	2-year LC, DFS, and OS were 91%, 71%, and 87%, respectively.
Haasbeek et al. [72]	SABR (at 7.5 Gy × 8 Fc) for centrally located early NSCLC.	Distant metastases and comorbidities were the predominant cause of death. 3-year LC and OS rates were 90.2% and 51.1, respectively.
Fakiris et al. [73]	Phase-2 prospective trial involving 70 early staged NSCLC treated with SABR (60–66 Gy).	SABR results in high rates of local control in medically inoperable patients of early NSCLC. Cancer specific survival at 3 years was 81.7%.
Bilal et al. [74]	Compared SABR and RFA for early stage inoperable NSCLC.	5-year OS was higher in SABR (47%) than RFA (27%).
Timmerman et al. [75]	Phase-2 prospective trial of Early stage NSCLC who were medically inoperable treated with SABR (18 Gy × 3 Fc).	3-year DFS and OS were 48.3% and 55.8%, respectively.

LC: local control; NSCLC: non-small cell lung carcinoma; DFS: disease free survival; OS: overall survival; RFA: radiofrequency ablation; Fc: fraction.